One group investigated the potential activity of an HDAC inhibitor, MS-275, in combination with a pan-carbonic anhydrase inhibitor, acetazolamide (AZ) in a pre-clinical NB xenograft model. This evidence concerns the gene HDAC9 and neuroblastoma.